


Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A percutaneous absorption type cerebral protective agent ~~characterized by containing~~ comprising, as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof in a base.

2. (Currently Amended) The percutaneous absorption type cerebral protective agent according to claim 1, ~~characterised in that~~ wherein the base is an aqueous base.


3. (Currently Amended) The percutaneous absorption type cerebral protective agent according to claim 2, ~~characterised in that~~ wherein the aqueous base ~~contains,~~ comprises, based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

4. (Currently Amended) The percutaneous absorption type cerebral protective agent according to claim 1, ~~characterised in that~~ wherein the base is a rubber base.

5. (Currently Amended) The percutaneous absorption type cerebral protective agent according to claim 4, ~~characterised in that~~ wherein the rubber base ~~contains,~~ comprises, based on the total amount of the rubber base, 10 to 50 percent by mass of a rubber polymer, 10 to 50 percent by mass of a plasticizer, and 5 to 50 percent by mass of a tackifier.

6. (Currently Amended) ~~A use of~~ A method of manufacturing a pharmaceutical composition, the method comprising:

combining a percutaneous absorption type pharmaceutical composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof ~~in an amount of 0.1 to 30 percent by mass in with a base, as an active ingredient for the manufacture of a percutaneous absorption type pharmaceutical composition for protecting brain in an amount of 0.1 to 30 percent by mass.~~

7. (Currently Amended) ~~The use method~~ according to claim 6, ~~characterised in that wherein~~ the base is an aqueous base.

8. (Currently Amended) ~~The use method~~ according to claim 7, ~~characterised in that wherein~~ the aqueous base ~~contains, comprises,~~ based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.


9. (Currently Amended) ~~The use method~~ according to claim 6, ~~characterised in that wherein~~ the base is a rubber base.

10. (Currently Amended) ~~The use method~~ according to claim 9, ~~characterised in that wherein~~ the rubber base ~~contains, comprises,~~ based on the total amount of the rubber base, 10 to 50 percent by mass of a rubber polymer, 10 to 50 percent by mass of a plasticizer,

and 5 to 50 percent by mass of a tackifier.

11. (Currently Amended) A method of protecting ~~brain against cerebral~~ dysfunction, comprising:

administering to a patient a percutaneous absorption type pharmaceutical composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof in an amount of 0.1 to 30 percent by mass in a base.

12. (Currently Amended) The method according to claim 11, ~~characterized in that~~ wherein the base is an aqueous base.

13. (Currently Amended) The method according to claim 12, ~~characterized in that~~ wherein the aqueous base ~~contains, comprises,~~ based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

14. (Currently Amended) The method according to claim 11, ~~characterized in that~~ wherein the base is a rubber base.

15. (Currently Amended) The method according to claim 14, ~~characterized in that~~ wherein the rubber base ~~contains, comprises,~~ based on the total amount of the rubber base, 10 to 50 percent by mass of a rubber polymer, 10 to 50 percent by mass of a plasticizer, and 5 to 50 percent by mass of a tackifier.